ATL and HTLV-I: In vivo cell growth of ATL cells
Journal of Clinical Immunology, ISSN: 0271-9142, Vol: 16, Issue: 6, Page: 305-314
1996
- 19Citations
- 9Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations19
- Citation Indexes19
- 19
- CrossRef17
- Captures9
- Readers9
Review Description
The mechanism of leukemogenesis or neoplastic cell growth in adult T cell leukemia (ATL) still remains unclear, although Tax of human T cell leukemia/lymphoma virus type I (HTLV-I), the etiologic virus, has been reported to affect the expression of various cellular genes which encode molecules involved in cell growth or cell death. We have studied the cell growth of HTLV-I-infected human T cells in severe combined immuno-deficiency (SCID) mice and found that fresh leukemic cells or cell lines derived from leukemic cell clones but not HTLV-I-infected cell lines of nonleukemic cell origin showed tumorigenicity, and neither HTLV-I nor IL-2 expression was needed for cell growth in vivo, indicating that accumulating changes in addition to tile initial events induced by HTLV-I infection were required for the development of ATL. The interaction between ATL cells and vascular endothelial cells appears to be one of the important factors which determine the pattern of organ infiltration by leukemic cells. E-selectin and its ligand are one of the major cell adhesion pathways between ATL cells and human umbilical vein endothelial cells (HUVEC). Another pathway that had not been identified was studied using newly developed monoclonal antibodies capable of blocking cell adhesion. The molecules which directly mediate adhesion between ATL cells and HUVEC were determined to be OX40 and gp34, a member of the tumor necrosis factor receptor (TNF-R) family and TNF family, respectively. The OX40/gp34 system may play a key role in the trafficking and homing of not only ATL cells but also activated normal T cells.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0029830253&origin=inward; http://dx.doi.org/10.1007/bf01541665; http://www.ncbi.nlm.nih.gov/pubmed/8946274; http://link.springer.com/10.1007/BF01541665; http://www.springerlink.com/index/pdf/10.1007/BF01541665; http://www.springerlink.com/index/10.1007/BF01541665; https://dx.doi.org/10.1007/bf01541665; https://link.springer.com/article/10.1007/BF01541665
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know